High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat. (c) 2007 Elsevier Ltd. All rights reserved.
There are provided according to the invention compounds of formula (I) in free or salt form, wherein R<1>, R<2>, R<3>, X, Y, Z, m, and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
作者:David A. Sandham、Clive Aldcroft、Urs Baettig、Lucy Barker、David Beer、Gurdip Bhalay、Zarin Brown、Gerald Dubois、David Budd、Louise Bidlake、Emma Campbell、Brian Cox、Brian Everatt、David Harrison、Catherine J. Leblanc、Jodie Manini、Rachael Profit、Rowan Stringer、Katy S. Thompson、Katharine L. Turner、Morris F. Tweed、Christoph Walker、Simon J. Watson、Steven Whitebread、Jennifer Willis、Gareth Williams、Caroline Wilson
DOI:10.1016/j.bmcl.2007.05.019
日期:2007.8
High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] CRTH2 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE CRTH2
申请人:NOVARTIS AG
公开号:WO2005105727A1
公开(公告)日:2005-11-10
There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, X, Y, Z, m, and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.